Homocysteine and coronary risk

Current Cardiology Reports

Volumn 1, Issue 2, 1999, Pages 91-98

  Seshadri, Niranjan ^a   Robinson, Killian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

AGE; BLOOD; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; LIFESTYLE; MALE; METABOLISM; REVIEW; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LIFE STYLE; MALE; RISK FACTORS; SEX FACTORS;

EID: 0033156266     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0065-1     Document Type: Article

References (59)

1. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
2. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996, 27:517-527.
3. Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Ann Rev Med 1998, 49:31-62.
4. Nygård O, Nordrehaug JE, Refsum H, et al.: Plasma homo-cysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
5. van der Griend R, Haas FJ, Duran M, et al.: Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998, 132:67-72.
6. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-1781.
7. Weisberg I, Tran P, Christensen B, et al.: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
8. Gudnason V, Stansbie D, Scott J, et al.: C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis 1998, 136:347-354.
9. Ou T, Yamakawa-Kobayashi K, Arinami T, et al.: Methylenetet-rahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998, 137:23-28.
10. Girelli D, Friso S, Trabetti E, et al.: Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998, 91: 4158-4163.
11. Brattström L, Wilcken D, Öhrvick J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The results of a meta-analysis. Circulation 1998, 98:2520-2526.
12. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, et al.: Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998, 83:550-553.
13. Nygard O, Vollset SE, Refsum H, et al.: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995, 274:1526-1533.
14. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996, 57:S11-17.
15. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997, 52:10-20.
16. Moustapha A, Naso A, Nahlawi M, et al.: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97:138-141.
17. Bostom AG, Shemin D, Lapane KL, et al.: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996, 123:193-202.
18. Moustapha A, Gupta A, Nahlawi M, et al.: Hyperhomo-cysteinemia and renal failure: metabolic determinants and effects of mode of dialysis. Circulation 1999, 55: 1470-1475.
19. van Guldener C, Donker AJ, Jakobs C, et al.: No net renal extraction of homocysteine in fasting humans. Kidney Int 1998, 54:166-169.
20. Fodinger M, Mannhalter C, Wolfl G, et al.: mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997, 52:517-523.
21. Hoogeveen EK, Kostense PJ, Jager A, et al.: Serum homo-cysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998, 54:203-209.
22. Wu J, Wu LL, Wilson W: Increased levels of plasma homo-cysteine in patients with various carcinomas [abstract]. Ir J Med Sci 1995, 164:29A.
23. Nedrebo BG, Ericsson UB, Nygard O, et al.: Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998, 47:89-93.
24. Cattaneo M, Vecchi M, Zighetti M, et al.: High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease. Neth J Med 1998, 52:S35.
25. Blankenhorn D, Malinow R, Mack W: Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Artery Dis 1991, 2:357-360.
26. Tonstad S, Refsum H, Ose L, Ueland PM: The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr 1998, 132:365-368.
27. Leonard J, Desager J, Beckers C, Harvengt C: In vitro binding of various biological substances by two hypocholesterolaemic resins. Arzneimittelforschung 1979, 29:979-981.
28. Carlsen SM, Folling I, Grill V, et al.: Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997, 57:521-527.
29. Ubbink JB, van der Merwe A, Delport R, et al.: The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996, 98:177-184.
30. Basu TK, Mann S: Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. J Nutr 1997, 127:117-121.
31. Miller JW, Shukitt-Hale B, Villalobos-Molina R, et al.: Effect of L-dopa and the catechol O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997, 20:55-66.
32. Arnadottir M, Hultberg B, Vladov V, et al.: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996, 61: 509-512.
33. Mijatovic V, Kenemans P, Netelenbos C, et al.: Postmenopausal oral 17-beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998, 69:876-882.
34. Mijatovic V, Kenemans P, Jakobs C, et al.: A randomized controlled study of the effects of 17-beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998, 91:432-436.
35. Giri S, Thompson PD, Taxel P, et al.: Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998, 137:359-366.
36. Cattaneo M, Baglietto L, Zighetti ML, et al.: Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998, 77:2264-2266.
37. Anker G, Lonning PE, Ueland PM, et al.: Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995, 60:365-368.
38. Tsai JC, Perrella MA, Yoshizumi M, et al.: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994, 91: 6369-6373.
39. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia [editorial]. J Clin Invest 1996, 98:5-7.
40. Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980, 18:113-121.
41. Stamler JS, Osborne JA, Jaraki O, et al.: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993, 91:308-318.
42. Upchurch GR Jr, Welch GN, Fabian AJ, et al.: Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272:17012-17017.
43. Rolland PH, Friggi A, Barlatier A, et al.: Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995, 91: 1161-1174.
44. Lentz SR, Sobey CG, Piegors DJ, et al.: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996, 98:24-29.
45. Lentz SR, Malinow MR, Piegors DJ, et al.: Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 1997, 17:2930-2934.
46. Tawakol A, Omland T, Gerhard M, et al.: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95:1119-1121.
47. Woo KS, Chook P, Lolin YI, et al.: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997, 96:2542-2544.
48. Ray JG, Harvey DT: Hyperhomocysteinemia as a cause of premature stroke in a young patient. Arch Phys Med Rehabil 1998, 79:343-345.
49. Evans RW, Shaten BJ, Hempel JD, et al.: Homocyst(e)ine and risk of cardiovascular disease in the multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997, 17:1947-1953.
50. Folsom AR, Nieto FJ, McGovern PG, et al.: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998, 98:204-210.
51. Petri M, Roubenoff R, Dallal GE, et al.: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996, 348:1120-1124.
52. Hoogeveen EK, Kostense PJ, Beks PJ, et al.: Hyperhomo-cysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
53. Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998, 316:894-898.
54. Lobo A, Naso A, Arheart K, et al.: Effect of low-dose folic acid on homocysteine levels in patients with coronary disease: a placebo-controlled study. Am J Cardiol 1999, 83:821-825.
55. Ward M, McNulty H, McPartlin J, et al.: Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM 1997, 90:519-524.
56. Bostom AG, Shemin D, Lapane KL, et al.: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147-152.
57. Woo K, Chook P, Lolin Y, et al.: Folic acid supplementation improves arterial endothelial function in hyperhomo-cysteinemic subjects [abstract]. Circulation 1997, 96:165.
58. Verhaar MC, Wever RM, Kastelein JJ, et al.: 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998, 97:237-241.
59. Peterson JC, Spence JD: Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia [letter]. Lancet 1998, 351:263.